Immunotherapy lifts four-year cervical cancer survival to 40%

Four years after starting treatment, 40% of women with advanced cervical cancer who had atezolizumab added to chemotherapy and bevacizumab were still alive. Among those who had chemotherapy and bevacizumab alone, the figure was 26%. Those numbers come from the final overall survival analysis of the phase 3 BEATcc trial, presented by Ana Oaknin at the ESMO Congress 2026 in Madrid on 24 October (abstract LBA38).

The trial's primary results were published in The Lancet. What's new is the length of follow-up. Median follow-up has now reached 57.2 months, almost five years, and 277 of the 410 women in the trial (68%) have died. That's enough to say with some confidence whether the early benefit lasted. It did.

What was tested

Cervical cancer that has spread to distant organs (metastatic), that wasn't cleared by earlier treatment (persistent), or that has come back after treatment (recurrent) usually can't be cured by surgery or radiotherapy. For about a decade the standard first treatment has been chemotherapy, typically cisplatin or carboplatin with paclitaxel, combined with bevacizumab. Bevacizumab (brand name Avastin) is an antibody that cuts off the blood supply tumours build to feed themselves.

BEATcc tested adding atezolizumab (brand name Tecentriq, made by Roche). Atezolizumab is an immunotherapy that blocks PD-L1, a protein tumours use to switch off T cells. Most cervical cancers are caused by human papillomavirus (HPV), and virus-driven tumours tend to be visible to the immune system, which is part of the reason immunotherapy was expected to help.

Women were randomised in equal numbers to standard chemotherapy plus bevacizumab, with or without atezolizumab at 1,200 mg through a drip every three weeks. Treatment carried on until the cancer progressed or side effects became unacceptable. The trial was run by academic trial groups in Europe, the US and Japan (ENGOT, GEICO, JGOG and GOG), which is reflected in its long official name.

Who took part

BEATcc enrolled 410 women with metastatic, persistent or recurrent cervical cancer who hadn't had previous drug treatment for advanced disease. Their cancer had to be measurable on scans and not suitable for curative surgery or radiotherapy. Randomisation was balanced for whether they'd previously had chemoradiation, for the cancer's cell type, and for which chemotherapy backbone they received, according to the Trialsgram summary of the abstract.

Unlike some immunotherapy trials in cervical cancer, BEATcc didn't require tumours to test positive for PD-L1. That's relevant later.

The trial is registered as NCT03556839 on ClinicalTrials.gov (EudraCT 2018-000367-83).

Results in plain numbers

BEATcc had two primary measures: progression-free survival and overall survival. The primary analysis in The Lancet reported progression-free survival of 13.7 months with atezolizumab against 10.4 months without (HR 0.62), according to The ASCO Post's coverage. The 2026 update is the planned final look at overall survival, triggered by whichever came first of at least 292 deaths or four years after the last patient joined.

Sources: ESMO 2026 abstract LBA38 as summarised by Trialsgram and OncoDaily; 2024 progression-free survival from The Lancet via The ASCO Post.

The hazard ratio of 0.69 means the risk of death at any point during follow-up was about 31% lower in the atezolizumab group. The median gain was 9.2 months. The four-year figures make the absolute difference concrete: for every 100 women treated, about 14 more were alive at four years.

PFS2 measures the time until the cancer progressed a second time, on whatever treatment came next, or death. A benefit here suggests that the early gain from atezolizumab wasn't simply cancelled out by worse results from later treatment.

Did PD-L1 status matter?

Many immunotherapy drugs work best in tumours with high levels of PD-L1, measured as a combined positive score (CPS). In BEATcc, an exploratory analysis found benefit in both groups.

The PD-L1 negative result looks remarkable, but it comes from a small group, as the wide confidence interval shows, and the analysis wasn't designed to prove anything on its own. OncoDaily's write-up of the presentation suggested PD-L1 testing may not be needed to choose patients for this combination, while urging caution. That fits the data, though it remains a hypothesis for now.

The effect of later immunotherapy

Women in the control group couldn't switch to atezolizumab when their cancer progressed. Many still got immunotherapy later: of the 110 control patients who had further treatment, 64 (58%) received an immunotherapy drug. If anything, that would narrow the survival gap between the arms, which makes the observed difference more convincing.

Side effects

The 2026 abstract describes long-term safety as consistent with the primary analysis and gives no new rates. The figures below come from the 2024 Lancet report.

Source: Oaknin et al., The Lancet 2024, as reported by The ASCO Post and the Lancet abstract.

Serious side effects were common in both arms, which reflects the intensity of the chemotherapy and bevacizumab backbone. Adding atezolizumab raised the rate only slightly. Milder side effects that were more frequent with atezolizumab included diarrhoea, joint pain, fever and rash. As with any PD-L1 blocking drug, there's also a risk of immune-related side effects in organs such as the thyroid, lungs, liver and bowel, which can occasionally be serious.

Bevacizumab has its own risks, including high blood pressure, bleeding and, in cervical cancer specifically, abnormal connections (fistulas) between the bowel, bladder or vagina. These apply to both arms of the trial, since both groups received it.

Limitations

BEATcc was open-label: women and their doctors knew whether atezolizumab was being given. That has little effect on overall survival but can influence progression assessments and side effect reporting.

The PD-L1 subgroup findings are exploratory, and the PD-L1 negative group is small.

The final survival result is from a congress abstract. As of early November 2026 it hadn't been published in full in a peer-reviewed journal, and the abstract doesn't give a P value for the final overall survival comparison, according to Trialsgram.

Long-term side effect rates weren't given in the abstract. We've relied on the 2024 primary analysis for side effect figures.

The standard of care has moved on. Since BEATcc was designed, pembrolizumab with chemotherapy, with or without bevacizumab, has become a first-line option, based on the KEYNOTE-826 trial. In its final overall survival analysis, published by Monk and colleagues in the Journal of Clinical Oncology, median survival among all 617 patients was 26.4 months with pembrolizumab against 16.8 months with placebo (hazard ratio 0.63), and 28.6 months against 16.5 months (hazard ratio 0.60) in the 548 whose tumours were PD-L1 positive (combined positive score of 1 or more). Several regulators approved it only for PD-L1 positive tumours. BEATcc didn't compare atezolizumab with pembrolizumab, and the trials differ in design, so their figures can't be lined up directly to say which is better.

Not everyone can have bevacizumab. Women with a high risk of bleeding or fistula, for example after extensive pelvic radiotherapy, may not be suitable, and the trial's results apply only to people who could receive it.

What it means for patients

For women with advanced cervical cancer starting first-line treatment, BEATcc now gives five years of evidence that adding atezolizumab to chemotherapy and bevacizumab extends life, with only a modest increase in serious side effects. The OncoDaily summary of the presentation describes the regimen as further supported as a first-line option for eligible patients.

Availability varies. Atezolizumab isn't licensed for cervical cancer in every country, and in the UK any NHS use would depend on an MHRA licence and NICE guidance. We couldn't confirm the current UK regulatory position for this use from the sources reviewed.

Questions worth asking:

• Which immunotherapy combination your team recommends, and why.
• What your tumour's PD-L1 score is, and whether it changes the options.
• Whether bevacizumab is safe for you, given any previous radiotherapy.
• How immune-related side effects would be monitored.

This article explains published research and isn't medical advice. Talk to your own specialist team about treatment decisions.